Reata Pharmaceuticals is a clinical-stage biopharmaceutical company based in Irving, Texas. They focus on developing innovative drugs that target molecular pathways involved in cellular metabolism and inflammation. Their two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, aim to restore mitochondrial function, reduce oxidative stress, and resolve inflammation by targeting the transcription factor Nrf2. In addition to cancer, inflammation, and neurodegenerative diseases, Reata also develops drugs for renal/cardiovascular, autoimmune, and protein misfolding disorders. The company was founded in 2002 and was previously known as Reata Discovery, Inc.